Ustekinumab for peristomal pyoderma gangrenosum

American Journal of Gastroenterology

Volumn 107, Issue 5, 2012, Pages 794-795

  Fahmy, Marianne ^a   Ramamoorthy, Sonia ^b   Hata, Tissa ^c   Sandborn, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Surgery   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; PREDNISONE; TACROLIMUS; USTEKINUMAB; MONOCLONAL ANTIBODY;

ABSCESS DRAINAGE; ADULT; CASE REPORT; COLON BIOPSY; CROHN DISEASE; DISEASE COURSE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HEADACHE; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; ILEOSTOMY; INTESTINE ENDOSCOPY; INTESTINE ULCER; KIDNEY FAILURE; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENTERAL NUTRITION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROCTOCOLECTOMY; PYODERMA GANGRENOSUM; RECURRENT DISEASE; TOTAL PARENTERAL NUTRITION; TREATMENT FAILURE; ULCERATIVE COLITIS; VAGINA DISEASE; COLON POUCH; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; COLONIC POUCHES; CROHN DISEASE; FEMALE; HUMANS; ILEOSTOMY; PYODERMA GANGRENOSUM;

EID: 84862309480     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.42     Document Type: Letter

References (7)

1. Mimouni D, Anhalt GJ, Kouba DJ et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003;148:813-6.
2. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 2004;49:1454-7.
3. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
4. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84.
5. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
6. Sandborn WJ, Gasink C, Gao LL et al. A multicenter, randomized, double-blind, placebo-controlled phase2b Study or Ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the certifitrial. Gastroenterology 2011;140:S109.
7. Guenova E, Teske A, Fehrenbacher B et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011;147:1203-5.